Natixis’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$52.3M Sell
213,825
-195,918
-48% -$45.6M 0.19% 77
2025
Q4
$84.8M Sell
409,743
-646,671
-61% -$128M 0.3% 43
2025
Q3
$196M Buy
1,056,414
+421,261
+66% +$72.2M 0.91% 15
2025
Q2
$97M Buy
635,153
+574,333
+944% +$88.3M 0.43% 37
2025
Q1
$10.1M Sell
60,820
-104,690
-63% -$16.4M 0.06% 226
2024
Q4
$23.9M Buy
165,510
+23,261
+16% +$3.6M 0.15% 114
2024
Q3
$23.1M Sell
142,249
-29,840
-17% -$4.75M 0.13% 114
2024
Q2
$25.2M Sell
172,089
-18,833
-10% -$2.8M 0.14% 117
2024
Q1
$30.2M Buy
190,922
+119,310
+167% +$19M 0.16% 113
2023
Q4
$11.2M Sell
71,612
-14,350
-17% -$2.2M 0.08% 199
2023
Q3
$13.4M Sell
85,962
-540,350
-86% -$89.2M 0.1% 163
2023
Q2
$104M Sell
626,312
-56,030
-8% -$9.04M 0.84% 20
2023
Q1
$106M Sell
682,342
-251,979
-27% -$40.7M 0.95% 13
2022
Q4
$165M Buy
934,321
+188,848
+25% +$32.6M 0.93% 18
2022
Q3
$122M Buy
745,473
+128,456
+21% +$21.7M 0.57% 24
2022
Q2
$109M Sell
617,017
-858,591
-58% -$153M 0.4% 29
2022
Q1
$262M Buy
1,475,608
+1,050,606
+247% +$179M 0.91% 14
2021
Q4
$72.7M Sell
425,002
-984,657
-70% -$161M 0.25% 66
2021
Q3
$228M Buy
1,409,659
+956,387
+211% +$163M 0.79% 14
2021
Q2
$74.7M Buy
453,272
+233,986
+107% +$38.7M 0.33% 72
2021
Q1
$36M Sell
219,286
-884,764
-80% -$143M 0.12% 177
2020
Q4
$174M Sell
1,104,050
-657,943
-37% -$97.1M 0.63% 29
2020
Q3
$262M Buy
1,761,993
+1,320,224
+299% +$195M 1.93% 3
2020
Q2
$62.1M Sell
441,769
-788,535
-64% -$115M 0.48% 40
2020
Q1
$161M Buy
1,230,304
+686,946
+126% +$97.5M 1.27% 10
2019
Q4
$79M Sell
543,358
-625,240
-54% -$84.8M 0.49% 40
2019
Q3
$151M Buy
1,168,598
+241,757
+26% +$31.9M 0.97% 15
2019
Q2
$129M Buy
926,841
+238,064
+35% +$33M 0.99% 18
2019
Q1
$95.7M Sell
688,777
-166,865
-20% -$22.4M 0.6% 30
2018
Q4
$110M Sell
855,642
-46,189
-5% -$6.44M 0.91% 18
2018
Q3
$125M Sell
901,831
-316,746
-26% -$42.1M 0.72% 37
2018
Q2
$148M Sell
1,218,577
-93,996
-7% -$11.7M 0.78% 23
2018
Q1
$168M Buy
1,312,573
+234,229
+22% +$31.7M 1.03% 16
2017
Q4
$151M Sell
1,078,344
-1,649,710
-60% -$230M 1.16% 12
2017
Q3
$355M Buy
2,728,054
+2,112,288
+343% +$280M 3.27% 1
2017
Q2
$81.5M Buy
615,766
+601,781
+4,303% +$76.8M 0.93% 22
2017
Q1
$1.74M Sell
13,985
-410,097
-97% -$49M 0.02% 323
2016
Q4
$48.9M Buy
424,082
+390,069
+1,147% +$45.1M 0.5% 48
2016
Q3
$4.02M Buy
+34,013
New +$4.13M 0.05% 214
2016
Q2
Sell
-27,051
Closed -$2.93M 424
2016
Q1
$2.93M Sell
27,051
-149,213
-85% -$15.4M 0.05% 177
2015
Q4
$18.1M Sell
176,264
-363,977
-67% -$36.6M 0.3% 52
2015
Q3
$50.4M Buy
540,241
+240,710
+80% +$23.3M 1.05% 22
2015
Q2
$29.2M Sell
299,531
-614,442
-67% -$61.5M 0.39% 54
2015
Q1
$91.9M Buy
913,973
+523,710
+134% +$53.3M 1.26% 15
2014
Q4
$40.8M Sell
390,263
-249,971
-39% -$26.3M 0.56% 34
2014
Q3
$68.2M Sell
640,234
-1,584,581
-71% -$164M 1.05% 18
2014
Q2
$233M Buy
2,224,815
+1,040,862
+88% +$105M 2.8% 4
2014
Q1
$116M Sell
1,183,953
-1,279,358
-52% -$119M 1.51% 12
2013
Q4
$226M Buy
2,463,311
+1,303,010
+112% +$120M 1.94% 7
2013
Q3
$101M Buy
1,160,301
+1,052,239
+974% +$94.4M 1.07% 13
2013
Q2
$9.28M Buy
+108,062
New +$9.17M 0.13% 155

Other funds holding JNJ

Natixis's JNJ Position: Q1 2026 in Review

Natixis reduced its Johnson & Johnson (JNJ) stake by 48% in Q1 2026, selling an estimated $45.6M and leaving 213,825 shares worth $52.3M. The position accounts for 0.19% of the portfolio, ranked #77.

Natixis first reported a position in JNJ in Q2 2013 and has held it in 51 quarters since. The position peaked at $355M in Q3 2017. 4,615 funds tracked by Wall St. Rank hold JNJ as of Q1 2026.

  • Natixis held 213,825 shares of Johnson & Johnson worth $52.3M as of Q1 2026.
  • Natixis sold 195,918 Johnson & Johnson shares in Q1 2026, an estimated $45.6M.
  • Johnson & Johnson made up 0.19% of Natixis's portfolio in Q1 2026, its #77 holding.
  • Natixis first reported a position in Johnson & Johnson in Q2 2013 and has held it in 51 quarters since.
  • Natixis's Johnson & Johnson position peaked at $355M in Q3 2017.
  • 4,615 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.